To assess the associations of semaglutide with incident CUD (first time diagnosis of CUD), the study population included 83,189 patients who had active medical encounters for the diagnosis of obesity in 6/202112/2022, were for the first time (new users design) prescribed semaglutide or non-GLP-1RA anti-obesity medications (bupropion, naltrexone, orlistat, topiramate, phentermine) [39] during 6/2021-12/2022 (time zero or index event), had no diagnosis of CUD on or before the index event and had a diagnosis of at least one of obesity-associated comorbidities (T2D, hypertension, hypercholesterolemia, hyperlipidemia, heart diseases, stroke) on or before the index event
CrossRef The Impact of National Surveillance for Liver Cancer: Results from Real-World Setting in Korea Jin Won Kwon, Ha Jin Tchoe, Jayoun Lee, Jae Kyung Suh, Jeong-Hoon Lee, Sangjin Shin Gut and Liver.2020
These questions can also help you better understand your eligibility for different medications
These work through different mechanisms (GLP-1 receptor activation vs
The medication must be coupled with a healthy diet, lifestyle intervention for a sustainable weight loss in the long run
Identifying the root cause of fatigue is crucial in ensuring your well-being and optimizing your overall treatment experience with semaglutide